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Synoviocyte-targeted therapy synergizes with TNF 
inhibition in arthritis reversal
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Karen M. Doody2, Kamil Slowikowski4,5,6,7,8, Fumitaka Mizoguchi4,9, Frances Humby10, 
Rebecca Hands10, Eugenio Santelli1,2, Cristiano Sacchetti1,2, Kuninobu Wakabayashi11, 
Dennis J. Wu1, Christopher Barback12,13, Rizi Ai14, Wei Wang14, Gary P. Sims15, Piotr Mydel16,17, 
Tsuyoshi Kasama11, David L. Boyle1, Francesco Galimi3, David Vera12,13, Michel L. Tremblay18,19,20, 
Soumya Raychaudhuri4,5,6,7,21,22, Michael B. Brenner4, Gary S. Firestein1, Costantino Pitzalis10, 
Anna-Karin H. Ekwall23,24, Stephanie M. Stanford1,2, Nunzio Bottini1,2*
Fibroblast-like synoviocytes (FLS) are joint-lining cells that promote rheumatoid arthritis (RA) pathology. Current 
disease-modifying antirheumatic agents (DMARDs) operate through systemic immunosuppression. FLS-targeted 
approaches could potentially be combined with DMARDs to improve control of RA without increasing immuno-
suppression. Here, we assessed the potential of immunoglobulin-like domains 1 and 2 (Ig1&2), a decoy protein 
that activates the receptor tyrosine phosphatase sigma (PTPRS) on FLS, for RA therapy. We report that PTPRS 
expression is enriched in synovial lining RA FLS and that Ig1&2 reduces migration of RA but not osteoarthritis 
FLS. Administration of an Fc-fusion Ig1&2 attenuated arthritis in mice without affecting innate or adaptive im-
munity. Furthermore, PTPRS was down-regulated in FLS by tumor necrosis factor (TNF) via a phosphatidylinositol 
3-kinase–mediated pathway, and TNF inhibition enhanced PTPRS expression in arthritic joints. Combination of 
ineffective doses of TNF inhibitor and Fc-Ig1&2 reversed arthritis in mice, providing an example of synergy be-
tween FLS-targeted and immunosuppressive DMARD therapies.
INTRODUCTION
Rheumatoid arthritis (RA) is the most common systemic autoimmune 
disease and is characterized by chronic inflammation, tumor-like 
enlargement of the joint synovial membrane (called pannus), and 
progressive destruction of joint cartilage and bone (1). Over the past 
two decades, multiple immunosuppressant disease-modifying anti-
rheumatic drugs (DMARDs) have been approved by the U.S. Food 
and Drug Administration for the treatment of RA (2). Among the 
most effective are biologic agents blocking the action of the inflam-
matory cytokine tumor necrosis factor (TNF) (3). While immuno-
suppressive DMARDs are generally very effective, they do increase 
the risk of infections. In addition, about one-third of patients with 
RA fail to achieve disease remission, despite trying multiple different 
immunosuppressants (4). Although combining multiple immuno-
suppressants would likely increase the rates of disease remission, this 
approach might further increase the risk of infections (5, 6). Thus, there 
is a current unmet medical need in RA for therapies that can be com-
bined with current DMARDs to spare immunosuppressants or improve 
control of disease without further suppressing the immune system.
One possible avenue to address this need is to target fibroblast-like 
synoviocytes (FLS), non-immune cells that reside in the intimal lining 
of the joint synovium (7). FLS are quiescent cells that control the 
composition of the synovial fluid and the extracellular matrix (ECM) 
of the joint lining. In RA, however, FLS become invasive, display-
ing a phenotype characteristic of transformed cells (7). RA FLS break 
down the ECM by producing matrix metalloproteinases, directly 
invade and digest articular cartilage, promote bone erosion, and en-
hance inflammation through secretion of interleukin-6 (IL-6), chemo-
kines, and other inflammatory mediators (7–9). A recent report 
provided rigorous demonstration that FLS promote arthritis se-
verity in mice and showed that joint lining versus sublining FLS 
play a different role in experimental arthritis, with lining FLS being 
critical mediators of cartilage damage and bone erosion (10).
It has been suggested that agents selectively targeting RA FLS could 
be combined with current DMARDs to improve disease control with-
out increasing the risk of infections (4, 7, 11). However, although a 
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few available DMARDs—including Janus kinase (JAK) inhibitors (12)—
have been shown to reduce FLS aggressiveness, there are currently 
no therapies available that selectively target FLS. The ideal agent 
for FLS-directed combination RA therapy would exhibit a mecha-
nism of action independent on innate and adaptive immunity, and 
its efficacy would not be impaired by concurrent DMARD adminis-
tration. Thus far, only cadherin-11—an adhesion molecule that acts as 
a critical regulator of synovial lining formation and FLS signaling—
has emerged as a potential target for selective anti-FLS therapy (13, 14).
We recently identified the transmembrane tyrosine phosphatase 
sigma (PTPRS) as a candidate target for FLS-directed RA therapy 
(15). PTPRS is expressed in the nervous system (16, 17) and stromal 
cells (15, 18), and its expression in peripheral immune cells from 
healthy subjects is restricted to plasmacytoid dendritic cells (pDCs) 
(19). PTPRS acts as a receptor for glycosaminoglycan (GAG) moieties 
of proteoglycans (PGs) in the ECM (16, 17, 20). Engagement of PTPRS 
N-terminal extracellular immunoglobulin (IgG)–like domains 1 and 2 
(Ig1&2) by ECM PG can modulate PTPRS function through a mecha-
nism that has been termed the PG switch (16). PTPRS is highly ex-
pressed on FLS, where its function is regulated by an interaction with 
the heparan sulfate transmembrane PG syndecan-4 (SDC4) (15). Dis-
ruption of the interaction between PTPRS and syndecan-4 by treatment 
of FLS with recombinant Ig1&2 decoy protein impaired FLS migra-
tion, invasiveness, and attachment to cartilage in a PTPRS-dependent 
manner (15). Furthermore, we demonstrated that treatment with 
Ig1&2 reversed established arthritis in the K/BxN serum transfer–
induced arthritis (STIA) model but was ineffective in PTPRS knock-
out (KO) mice, providing evidence of target specificity (15). These 
findings suggest potential for PTPRS as a therapeutic target for FLS- 
directed RA therapy by impairing FLS invasiveness into cartilage.
Here, we assessed the potential of Ig1&2 as an FLS-targeted 
agent for combination RA therapy. We demonstrate that Ig1&2 has 
all the features of an ideal agent for FLS-targeted therapy, including 
target enrichment in lining RA FLS, selective effectiveness on RA 
FLS versus osteoarthritis (OA) FLS, and efficacy in multiple models 
of RA without any detectable immunosuppressive mechanism of 
action. Furthermore, because of the regulatory role of TNF signal-
ing on PTPRS expression in RA FLS, we demonstrate that Ig1&2 
can synergize with TNF inhibition in reversing arthritis when ad-
ministered as a combination therapy.
RESULTS
PTPRS is enriched in lining layer FLS in the RA synovium
To further establish PTPRS as a target for FLS-directed therapy for 
RA, we first examined the expression profile of PTPRS in the rheumatic 
synovium. As shown in Fig. 1A, immunofluorescent (IF) staining 
revealed prominent expression of PTPRS in the lining layer of the 
RA synovium and only sparse staining in the sublining, which was 
confirmed by immunohistochemical staining for PTPRS (fig. S1, A 
and B). Furthermore, staining for PTPRS was mainly found to colo-
calize with podoplanin staining on cells within the lining layer of the 
synovium (Fig. 1A and fig. S1A). As podoplanin is considered to be 
a marker for aggressive FLS in RA (21), these results suggest that 
PTPRS expression is mainly found on aggressive FLS within the lin-
ing layer of the RA synovium. Consistent with our previous report 
that PTPRS expression is induced by chronic inflammatory arthritis 
in mice (15), no expression of PTPRS was observed in the synovial 
tissue from patients with OA, which correlated with a lack of podo-
planin expression (Fig. 1A). The enriched expression of PTPRS in 
synovial lining RA FLS [CDH11+CD34−THY1− (22)] when com-
pared to sublining RA FLS [CDH11+CD34−THY1+ (22)] was fur-
ther confirmed by mining RNA sequencing (RNA-seq) data from 
RA FLS freshly isolated from the synovial tissue of patients with RA 
(Fig. 1B) (22).
Ig1&2 inhibits motility of RA FLS but not OA FLS
To increase the therapeutic potential and drug-like properties of Ig1&2, 
we generated an Fc-fused Ig1&2 by replacing our previously described 
6xHis-tag (15) at the protein C terminus with a human IgG1 Fc (Fig. 1C). 
Fc-Ig1&2 showed similar efficacy in suppressing RA FLS migration 
in vitro as His-Ig1&2, an effect that was not mediated through the 
Fc portion of the protein (fig. S1C). In addition, Fc-Ig1&2 was effec-
tive in limiting invasion of RA FLS through type I collagen–based 
matrix (Fig. 1D). This effect on Fc-Ig1&2 of FLS migration and in-
vasion was not due to an alteration in cell numbers, because Fc-Ig1&2 
did not affect RA FLS proliferation (fig. S1D).
To assess whether the mechanism of action of Ig1&2 is selective 
for RA FLS, we next compared the effect of Ig1&2 on the migratory 
potential of RA FLS versus OA FLS and normal human dermal fi-
broblasts (NHDF) using a scratch wound assay. Although Fc-Ig1&2 
was very effective in inhibiting the migration and invasion of RA FLS 
in response to serum, unexpectedly, it did not alter the migratory 
and/or invasive potential of OA FLS or/and NHDF (Fig. 1, E to G, 
and fig. S1, E to H). Although a notable difference in expression of 
PTPRS was observed between RA and OA synovium (Fig. 1A), RA 
and OA FLS unexpectedly displayed similar mRNA expression of 
PTPRS [(15) and fig. S1I]. The higher expression of PTPRS in cul-
tured versus synovial OA FLS is likely due to cell confluency, which 
we have previously shown an important inducer of PTPRS expres-
sion (15). However, we cannot, at the moment, rule out positive selection 
of high PTPRS expressor OA FLS subsets during culturing and/or 
modulation of PTPRS expression by the local OA microenvironment. 
Nevertheless, our results point to cultured RA FLS having a distinct 
phenotype from OA FLS, which renders them susceptible to PTPRS- 
mediated migratory inhibition.
We have previously shown that the effect of Ig1&2 is critically 
dependent on the PG syndecan-4 (15). Consistent with the selective 
effect of Ig1&2 on RA FLS, we found an increased expression of 
SDC4 in RA FLS when compared to both OA FLS and NHDF (fig. 
S1, J and K). We next explored the epigenomic and transcriptomic 
landscape of the SDC4 locus in RA and OA FLS using our recently 
published dataset (23). We found that RA FLS showed a 1.2-fold 
increased signal (P < 0.01) for the epigenetic histone mark H3K4me3 
(Fig. 1, H and I), which associates with transcriptional start sites 
of actively transcribed genes (24). Such increased signal was asso-
ciated with increased RNA-seq expression signal (1.4-fold, P < 0.05) 
for SDC4 in RA FLS from the same dataset (Fig. 1J). Together, 
these results suggest that the effect of Ig1&2 is specific to RA 
FLS because of an epigenetically driven increased expression of 
syndecan-4.
Fc-Ig1&2 shows high accumulation in arthritic paws 
and suppresses experimental arthritis
Next, we sought to characterize the efficacy of Fc-Ig1&2 in experi-
mental mouse arthritis. Similar to results for 6xHis-Ig1&2 (15), we 
found that Fc-Ig1&2 was highly effective in suppressing K/BxN STIA 
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biodistribution of Fc-Ig1&2 during arthritis, we injected 111-indium 
(111In)–labeled Fc-Ig1&2 in mice with established STIA. Radiolabeling 
of Fc-Ig1&2 did not affect the function of the protein (fig. S2B). As 
controls, we used an 111In-labeled murine homolog of etanercept 
(murine p75TNFR:Fc; here called Fc-mTNFR) (Fig. 2A and fig. S2B). 
As shown in Fig. 2, A and B, Fc-Ig1&2 showed significantly increased 
accumulation in the joints of arthritic mice in comparison to Fc-mTNFR. 
111In-Fc-Ig1&2 was nearly absent in mouse brains and eyes, suggest-
ing that Fc-Ig1&2 does not cross the blood-brain barrier (fig. S2C).
We next assessed the efficacy of Ig1&2 in reversal of mouse collagen- 
induced arthritis (CIA), which is driven by the adaptive immune 
system and considered the gold standard for preclinical therapeutic 
development for RA (25). Administration of Fc-Ig1&2 to arthritic CIA 
mice caused a significant reduction in disease severity, comparable 
Fig. 1. Ig1&2 selectively inhibits the aggressive behavior of RA FLS but not OA FLS. (A) Representative IF images of expression of PTPRS (green) and podoplanin (red) 
expression in RA (n = 5) and OA (n = 4) synovial tissue. Hoechst was used for nuclear stain and mouse IgG (mIgG) as control for PTPRS. Scale bar, 100 m. (B) Expression of 
PTPRS by RNA-seq in lining (cadherin-11+CD34−THY−) and sublining (cadherin-11+CD34−THY+) layer FLS isolated from RA synovial tissue (n = 7). TPM, transcripts per 
million. (C) Scheme of human Fc-Ig1&2 fusion protein. (D) Invasion of RA FLS (n = 6) through type I collagen in response to 10% FBS in the presence or absence of 
Fc-Ig1&2 (20 nM). (E) Wound healing by RA (n = 10) and OA (n = 8) FLS in response to 1% FBS in the presence or absence of Fc-Ig1&2 (20 nM). ns, not significant. (F and 
G) Transwell migration (F) and invasion through Matrigel (G) by RA (migration, n = 9; invasion, n = 9) and OA (migration, n = 10; invasion, n = 8) FLS in response to 10% FBS 
in the presence or absence of Fc-Ig1&2. (H) Epigenomic landscape of the syndecan-4 (SDC4) locus in representative OA and RA FLS lines. (I and J) H3K4me3 signal in SDC4 
(I) and SDC4 expression by RNA-seq (J) in RA (n = 10) and OA (n = 10) FLS. (D to G) Fold change relative to vehicle-treated controls. Graphs represent means ± SEM. *P < 0.05, 
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to treatment with Fc-mTNFR using a dose (4 mg/kg) that has been 
shown to be effective in CIA (Fig. 2C) (26). The efficacy of Fc-
Ig1&2 in CIA was not associated with decreased production of anti- 
collagen antibodies (Fig. 2D). Fc-Ig1&2 administration also protected 
mice from inflammation (2.6-fold reduction, P < 0.01), cartilage 
damage (2.2-fold reduction, P < 0.05), and bone erosions (2.1-fold 
reduction, P < 0.05) as assessed by histopathology and micro– 
computed tomography (Micro-CT) analysis of joints (1.2-fold reduc-
tion, P < 0.05; Fig. 2, E and F). Together, these results suggest that Ig1&2 
has a favorable biodistribution profile and exerts a therapeutic effect 
Fig. 2. Fc-Ig1&2 accumulates in arthritic ankles and suppresses development of arthritis. (A) BALB/c mice with established STIA were intravenously injected with the 
same amount of either 111In-labeled Fc-mTNFR (280 Ci; n = 5) or Fc-Ig1&2 (165 Ci; n = 4). Representative images of measurement 6 hours after injection. (B) Comparison 
of accumulation of labeled proteins from (A) in hind paws of arthritic mice. (C) Clinical score of DBA/1J mice with CIA treated with either 0.5 mg of Fc-Ig1&2 (n = 6), Fc-mTNFR 
(4 mg/kg; n = 6), 0.5 mg of human IgG1-Fc control (Fc-hIgG1; n = 6), or vehicle (n = 6) by intraperitoneal injection once every other day for a total of five treatments as in-
dicated. (D) Serum level of anti-collagen antibodies of mice in (C). OD, optical density. CII, type II collagen. (E and F) Representative Micro-CT, hematoxylin and eosin (H&E), 
and Safranin O (SO) images used for quantification (F) of synovial inflammation, bone erosion, and cartilage depletion of mice in (C). Scale bars, 500 m. Bone erosions 
were evaluated by Micro-CT by measuring the change in bone surface (BS) divided by bone volume (BV) (1/mm). Graphs represent means ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001 by two-way analysis of variance (ANOVA) [(C) orange asterisks indicate significance for Fc-Ig1&2 versus Fc-IgG1 and vehicle, while blue 
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in multiple models of arthritis driven by the innate and/or adap-
tive immune system.
Ig1&2 attenuates inflammatory arthritis without 
suppressing the innate immune system
We next sought to thoroughly characterize whether the therapeutic ef-
fect of Ig1&2 is mediated through suppression of the innate or adap-
tive immune system. Previous transcriptomic studies have suggested 
that PTPRS expression is virtually absent from the majority of immune 
cells in healthy humans and mice, with the exception of pDCs (19).
To evaluate whether the effect of Ig1&2 is mediated through the 
innate immune system, we used again the STIA model, in which 
disease pathogenesis is heavily dependent on the actions of FLS and 
innate immune cells but independent of adaptive immune cells 
(13, 27). Nonclassical Ly6C− monocytes and bone marrow–derived 
major histocompatibility complex II+ (MHCII+)CD64+ macrophages 
are crucial mediators of arthritis in this model, while tissue-resident 
MHCII−CD64+ macrophages play a protective role (28). However, 
neither classical (Ly6C+CD43−), intermediate (Ly6C+CD43+), or 
nonclassical (Ly6C−CD43+) circulating monocytes showed detect-
able expression of PTPRS (fig. S3A) in STIA mice. Furthermore, 
PTPRS was absent on MHCII+CD64+ macrophages and expressed 
at low levels in a small subset of MHCII−CD64+ macrophages iso-
lated from arthritic ankles of STIA mice (fig. S3A). Next, to dissect 
the effect of Ig1&2 on FLS versus radiosensitive bone marrow– 
derived cells in vivo, we compared the efficacy of Ig1&2 at attenuat-
ing STIA in CD45.1 congenic mice subjected to lethal irradiation 
[>10 gray (Gy)] and bone marrow transplantation from CD45.2 wild-
type (WT) or PTPRS KO mice (Fig. 3A and fig. S3B). Mice reconsti-
tuted with WT or KO bone marrow displayed identical arthritis 
severity once subjected to STIA (Fig. 3A). Furthermore, Ig1&2 dis-
played identical anti-arthritic action in the two groups of mice 
(Fig. 3A). To complete our assessment of whether innate immunity 
mediates the anti-arthritic action of Ig1&2, we turned to pDC, which 
express high levels of PTPRS [(19) and fig. S3A]. To assess whether 
pDC contribute to the anti-arthritic action of Ig1&2 in vivo, we 
depleted pDC using an anti–PDCA-1 (plasmacytoid dendritic cell 
antigen-1) antibody (29) before subjecting mice to STIA (fig. S3C). 
We found no difference in arthritis development between pDC- 
depleted and nondepleted mice, and the anti-arthritic effect of Ig1&2 
was maintained in pDC-depleted mice (fig. S3D).
To further rule out any potential effects of Ig1&2 on activated 
macrophages, we also evaluated macrophage polarization and bac-
terial phagocytosis. First, Fc-Ig1&2 was added during the polariza-
tion of bone marrow–derived macrophages (BMDMs) into either 
M1 or M2 effector phenotypes. For both effector phenotypes, the 
addition of Fc-Ig1&2 did not affect the up-regulation of character-
istic transcription factors or cytokines (fig. S4, A and B). Similarly, 
Fc-Ig1&2 did not alter the phagocytosis of either Escherichia coli or 
Staphylococcus aureus by M0, M1, or M2 macrophages (fig. S4, C 
and D). This suggests that Ig1&2 does not alter functions of innate 
immune cells and that its therapeutic effect in mouse arthritis is not 
mediated through suppression of the innate immune system.
The therapeutic effect of Ig1&2 in mouse arthritis is not 
mediated through the adaptive immune system
We next assessed whether Ig1&2 exerts an effect on arthritis devel-
opment through an action on the adaptive immune system. First, 
Fig. 3. The therapeutic effect of Ig1&2 in K/BxN arthritis is not mediated through the immune system. (A) Top panel shows scheme for evaluating the effect of Ig1&2 
on development of K/BxN STIA in WT mice reconstituted with either PTPRS WT or KO bone marrow (BM). Mice were treated with either vehicle or 0.5 mg of histidine 
tagged Ig1&2 (His-Ig1&2) by retro-orbital (r.o.) injection once every other day for a total of four treatments. Clinical score (left bottom panel) and change in ankle swelling 
(right bottom panel) is shown for groups; WT BM treated with vehicle (n = 4), WT BM treated with His-Ig1&2 (n = 5), KO BM treated with vehicle (n = 6), and KO BM treated 
with His-Ig1&2 (n = 7). (B) At 7 weeks of age, mice with active K/BxN arthritis were treated with 0.5 mg of His-Ig1&2 (n = 5) or vehicle (n = 5) r.o. every 2 days for a total of 
four treatments. After 10 days, sera were collected, and 100 l was used to induce STIA in BALB/c mice (n = 5 per group). Arthritis in K/BxN and BALB/c mice was assessed 
by clinical scoring (top) and change in ankle thickness (bottom). Arthritis severity in (A) calculated using area under the curve. *P < 0.05, **P < 0.01, ***P < 0.001, and 
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we administered Ig1&2 to arthritic K/BxN transgenic mice, which 
develop spontaneous arthritis starting at 6 to 7 weeks of age (27). 
We observed a significant reversal of spontaneous arthritis in these 
mice after treatment with Ig1&2 (Fig. 3B). However, when sera of 
Ig1&2-treated K/BxN mice were transferred into WT recipient mice 
to induce STIA, we did not observe any difference in the arthritoge-
nicity of sera from the Ig1&2-treated versus vehicle-treated K/BxN 
mice (Fig. 3B). Thus, reversal of spontaneous K/BxN arthritis by Ig1&2 
is not mediated by decreased titers of arthritogenic antibodies.
Next, we used mouse CIA to further determine the effect of Fc-
Ig1&2 on the adaptive immune system during arthritis. The therapeutic 
efficacy of Fc-Ig1&2 was not associated with an altered accumulation 
or expansion of regulatory T cells (Tregs) or T helper 17 (TH17) cells 
in arthritic ankles of CIA mice (Fig. 4, A and B, and fig. S5A). Con-
sistent with the STIA data, treatment with therapeutic doses of Fc-
Ig1&2 did not alter the number or frequency of MHCII+CD64+ and 
MHCII−CD64+ macrophages in the same ankles (Fig. 4C and fig. S5B). 
Furthermore, the therapeutic effect of Fc-Ig1&2 was not associated 
Fig. 4. The therapeutic effect of Ig1&2 in CIA is not mediated through the immune system. (A) Therapeutic treatment of DBA/1J mice with CIA by intraperitoneal injections 
of 0.5 mg of Fc-Ig1&2 (n = 9) or vehicle control (n = 8) every other day for a total of three injections. Mice were euthanized 4 days after the last treatment, which corresponds 
to 56 days after primary immunization. (B) Number of regulatory T cells (Tregs; Tcr+CD4+IL-17−FoxP3+) and TH17 (Tcr+CD4+IL-17+FoxP3−) cells in arthritic ankles isolated from 
mice in (A). (C) MHCII+ and MHCII− (tissue-resident) synovial macrophages (CD45+CD11b+Ly6G−Ly6C−CD64+) in arthritic ankles isolated from mice in (A). (D) Treatment of 
DBA/1J mice by intraperitoneal injections with either 0.5 mg of Fc-Ig1&2 (n = 9) or vehicle control (n = 10) during the primary and boost collagen immunization. Mice were 
treated every other day with one treatment the day before immunization and two treatments after immunization. (E to H) Number of follicular T cells [(Tfh); (E)], GC B cells (F), TH1 
and TH17 cells (G), and Tregs (H) in joint draining lymph nodes of mice in (D). Graphs represent means ± SEM. **P < 0.01 and ***P < 0.001 by two-way ANOVA (A). PD-1, 
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with an alteration in the expansion of naïve and effector CD4 T cells 
or the expansion of the CD4 T cell effector populations TH1 or TH17 
cells in the spleen and lymph nodes of arthritic CIA mice (fig. S5, C 
to F). Similarly, we did not observe any effects on germinal center 
(GC) B cell or CD4 T follicular helper (Tfh) cell numbers (fig. S5, 
G to J), which are important for the generation of pathogenic auto-
antibodies in the CIA model (30). Last, there was no change in Treg 
numbers or in the expression of CTLA4 by Tregs, in arthritic CIA 
mice after treatment with Fc-Ig1&2 (fig. S5, K and L). Together, 
these results suggest that the therapeutic action of Fc-Ig1&2 in CIA 
is not mediated through an effect on CD4 effector populations or 
GC B cells.
Ig1&2 does not alter adaptive responses to immunization
To determine whether Ig1&2 could potentially affect the immune 
response following immunization—which is affected by immuno-
suppressive DMARDs (31)—we next treated DBA/1J mice with Fc-
Ig1&2 during the primary and boost immunization against type II 
collagen and followed the generation of anti-collagen type II anti-
bodies (fig. S6A). Consistent with the data shown in Fig. 2D, we did 
not observe any effect of Fc-Ig1&2 on overall titers of anti-collagen 
IgG antibodies (Fig. 4D) or the titers of anti-collagen IgG subclasses 
IgG1, IgG2a, IgG2b, and IgG3 (fig. S6B). We also did not observe 
any effect of Fc-Ig1&2 on the frequency and numbers of Tfh cells or 
GC B cells (Fig. 4, E and F, and fig. S6, C and D). Together, these 
results suggest that Ig1&2 does not affect humoral responses to im-
munization with type II collagen.
Ig1&2 does not alter the polarization of CD4 T cells
Recently, it was shown that PTPRS KO CD4 T cells show enhanced 
polarization into TH1 and TH17 cells (32). To determine whether 
Ig1&2 affects CD4 T cell polarization during immunization with 
collagen, we evaluated CD4 T cell populations in mice treated with 
Fc-Ig1&2 during primary and boost immunizations. We did not 
observe skewing of naïve or effector CD4 T cell populations in the 
spleen and lymph nodes of Fc-Ig1&2–treated mice (fig. S6, E and F). 
Also, we did not observe any alterations in the numbers of TH1, 
TH17, or Tregs in either lymph nodes (Fig. 4, G and H, and fig. S6H) or 
spleen (fig. S6, G and H) of the same mice. Tregs from lymph nodes and 
spleen of mice treated with either Fc-Ig1&2 or vehicle displayed sim-
ilar levels of CTLA4 (cytotoxic T-lymphocyte-associated protein 4) 
expression (fig. S6H). To further dissect the effect of Ig1&2 on the 
polarization of CD4 T cells, we performed in vitro polarization assays 
of CD4 T cells stimulated with plate-bound antibodies or antigen- 
presenting cells (APCs). Similar to our in vivo observations, Ig1&2 
did not alter the polarization of CD4 T cells isolated from BALB/c or 
DBA/1J mice into TH1, TH17, or Treg cells, regardless of the presence or 
absence of APCs (fig. S7, A to D). Together, these results suggest that 
Ig1&2 does not affect the polarization of CD4 T cells in vitro or 
in vivo and support the idea that the therapeutic effect of Fc-Ig1&2 
is unlikely to be mediated through immunosuppression.
TNF down-regulates PTPRS expression in RA FLS 
and decreases their sensitivity to Ig1&2
TNF inhibitors are a major class of immunosuppressive DMARDs 
for treatment of RA. To evaluate whether Ig1&2 could be used in 
combination with anti-TNF therapy, we first determined whether 
TNF modulates PTPRS expression. As shown in Fig. 5 (A to C), 
stimulation with TNF caused concentration and time-dependent 
down-regulation of PTPRS expression in RA FLS at the mRNA and 
protein level, which was unaffected by the presence of normal growth 
media during TNF stimulation (fig. S8A). This effect of TNF on the 
expression of PTPRS at the mRNA level was further confirmed a 
Japanese cohort of RA FLS and in mouse FLS (fig. S8, B and C). In 
addition, activation of RA FLS with knee synovial fluids from patients 
with active RA—as shown by the increased production of IL6—
resulted in a reduction of PTPRS (Fig. 5D and fig. S8D). Consistent 
with the inhibitory effect of TNF on PTPRS expression in RA FLS, 
we found a negative correlation between the mRNA expression of 
PTPRS and TNF quantified by quantitative polymerase chain reac-
tion (qPCR) in the synovial tissue of patients with RA (Fig. 5E and 
fig. S8E). Down-regulation of PTPRS expression by TNF correlated 
with reduced sensitivity of RA FLS to migration inhibition by Ig1&2. 
However, consistent with the efficacy of Ig1&2 in the TNF-enriched 
joints of CIA mice, TNF-treated RA FLS retained significant re-
sponsiveness to ≥10 nM Ig1&2 in motility assays in vitro (Fig. 5, F 
to H). We conclude that, although TNF stimulation might reduce 
the sensitivity of RA FLS to Ig1&2, sufficient expression of PTPRS 
is retained on TNF-stimulated RA FLS to limit their motility once 
the cells are incubated with optimal amounts of PTPRS-activating 
Ig1&2.
TNF regulates PTPRS expression in RA FLS through the  
PI3K/GSK3/USF2 pathway
The regulation of PTPRS expression has not yet been addressed. To 
further investigate the potential signaling pathway by which TNF af-
fects PTPRS expression, we inhibited two TNF-dependent pathways—
the nuclear factor B (NFB) and phosphatidylinositol 3-kinase (PI3K) 
signaling pathways—in RA FLS. Inhibition of the NFB pathway had 
no effect on the expression of PTPRS after TNF stimulation (Fig. 6A). 
However, inhibition of PI3K prevented down-regulation of PTPRS 
induced by TNF. Previous studies have identified that PI3K is re-
quired for TNF-induced activation of AKT in RA FLS and important 
for the proliferation, migration, and invasion of RA FLS (33). Inhibi-
tion of glycogen synthase kinase 3 (GSK3) through phosphorylation 
at Ser9 is a major consequence of PI3K/AKT pathway activation (34), 
and increased GSK3 pSer9 phosphorylation correlates with increased 
activation of the PTPRS-target ezrin in RA FLS (33, 35). Accordingly, 
inhibition of GSK3 resulted in significant down-regulation of PTPRS 
expression in resting RA FLS (Fig. 6B). Further evaluation of the 
epigenomic landscape of the PTPRS locus in RA FLS [n = 10; data 
from our recently published dataset, (23)] revealed histone marks 
for active promoters (H3K4me3), primed enhancers (H3Kme1), and 
repressive marks (H3K27me3) around exon 1 of the PTPRS gene. 
Using the ENCODE (Encyclopedia of DNA Elements) database 
and the University of California, Santa Cruz (UCSC) human ge-
nome browser, we identified potential binding sites for two down-
stream targets of GSK3, upstream stimulatory factor 1 (USF1) 
and USF2 (36), in the promoter region of PTPRS, suggesting in-
volvement of these two transcription factors in the regulation of 
PTPRS expression (Fig. 6C). This was further supported by a posi-
tive correlation between the expression of either USF1 or USF2 with 
PTPRS in RA and OA FLS, as detected by analysis of our recently pub-
lished RNA-seq data (fig. S9A) (23). By using small interfering RNA 
(siRNA)–mediated knockdown of USF2, we found that USF2 indeed 
promotes the expression of PTPRS in RA FLS (Fig. 6D and fig. S9B). 
Using chromatin immunoprecipitation (ChIP), we further confirmed 
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and that such interaction was significantly reduced after stimulation 
with TNF (Fig. 6E and fig. S9C). Last, using a luciferase reporter con-
struct encompassing the PTPRS promoter region, we demonstrated 
that overexpression of USF2 causes a strong activation of the PTPRS 
promoter (Fig. 6F). Together, these results suggest that expression 
of PTPRS in RA FLS is regulated by TNF via a PI3K/GSK3/USF2 
pathway.
Therapeutic synergy between Fc-Ig1&2 and  
Fc-mTNFR in CIA
The inverse correlation between TNF stimulation and PTPRS ex-
pression in RA FLS suggests the intriguing scenario where combi-
nation therapy with TNF inhibitors could synergize with Ig1&2 by 
inducing PTPRS expression on RA FLS. To test this hypothesis ex-
perimentally, we first determined whether TNF inhibition induces 
the expression of PTPRS in CIA joints. An initial dose response of 
Fc-mTNFR in CIA showed that a clinically ineffective dose of 
Fc-mTNFR (2 mg/kg) was sufficient to enhance Ptprs expression in 
arthritic joints of mice (fig. S10, A and B).
Next, to evaluate the potential synergy between Ig1&2 and TNF 
inhibition in CIA, we treated arthritic CIA mice with either a sub-
optimal dose of Fc-Ig1&2 (0.1 mg), Fc-mTNFR (2 mg/kg), or a 
combination of the two (Fig. 7A). Monotherapy with either sub-
optimal Fc-Ig1&2 or Fc-mTNFR (2 mg/kg) did not cause significant 
reversal of disease in CIA. However, the combination of the two 
clinically ineffective doses of Fc-Ig1&2 and Fc-mTNFR caused a 
notable reversal of clinical CIA (Fig. 7A). The combination therapy, 
but not the monotherapies, also protected mice from cartilage damage 
and bone erosions, as assessed by histopathologic analysis of joints 
(Fig. 7, B and C). Consistent with the lack of effect of Fc-Ig1&2 on 
the abovementioned adaptive immune responses, the combined 
Fc-mTNFR–Fc-Ig1&2 treatment did not lead to a reduction in anti- 
collagen antibody titers (Fig. 7D). We conclude that combination of 
ineffective doses of Fc-Ig1&2 and Fc-mTNFR enables reversal of 
inflammation, bone damage, and cartilage erosion when adminis-
tered after onset of established disease, suggesting the potential for 
pharmacologic synergism between TNF inhibition and PTPRS-targeted 
therapies for RA treatment.
DISCUSSION
The advent of immunosuppressant DMARDs in the past two de-
cades has undoubtedly revolutionized management of RA. However, 
an unmet need persists in RA, because immunosuppressant DMARDs 
increase the risk of infection and a significant fraction of patients 
still fails to achieve persistent remission despite trying multiple dif-
ferent DMARDs (4). Combining current DMARDs with novel agents 
against FLS targets that are not expressed or irrelevant in immune 
cells is considered a promising strategy to enhance the efficacy of 
immunosuppressant DMARDs (4). An important indication for 
FLS-targeting agents would be incomplete response to immuno-
suppressant DMARDs, because targeting FLS could enhance the 
effect of anti-cytokine therapeutics by blocking inflammation down-
stream additional stimuli. However, FLS-targeting therapy could 
also be useful as a DMARD-sparing strategy in patients experiencing 
an unacceptable rate/seriousness of infections. Furthermore, RA 
Fig. 5. TNF down-regulates expression of PTPRS in RA FLS. (A and B) Gene (A) and protein (B) expression of PTPRS in RA FLS (n = 13) stimulated with TNF for 12 [gene, 
(A)] or 24 hours [protein, (B)]. RQ, relative quantification. (C) Time-dependent down-regulation of PTPRS in RA FLS (n = 7) stimulated with TNF (5 ng/ml). (D) Expression of 
PTPRS in RA FLS (n = 6) stimulated with synovial fluid (SF) obtained from three individual patients with RA with active disease RA1 (squares; n = 3 FLS lines), RA2 (triangles; 
n = 2 FLS lines), and RA3 (diamond; n = 1 FLS line) for 12 hours. (E) Correlation between expression of TNF and PTPRS in RA synovial tissue (n = 42). Linear regression is 
shown. (F) RA FLS were stimulated with TNF (50 ng/ml) for 24 hours, after which scratch-wounding healing was evaluated in response to 1% FBS and TNF (50 ng/ml) in 
the presence or absence of 20 nM Fc-Ig1&2. (G) RA FLS were prestimulated with TNF (50 ng/ml) for 24 hours, after which cells were subjected to transwell migration in 
response to 10% FBS in the presence or absence of TNF (50 ng/ml) and Fc-Ig1&2. (H) Relative change in migration between RA FLS migrated in the presence or absence 
of TNF and Fc-Ig1&2. Gene expression in (A), (C), (D), and (E) relative to GAPDH. Graphs represent means ± SEM. *P < 0.05, **P < 0.01, and ****P < 0.0001 by paired one-way 









Svensson et al., Sci. Adv. 2020; 6 : eaba4353     26 June 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 17
FLS also develop permanent epigenetic modifications that enhance 
invasiveness (7) and might drive smoldering inflammation and cause 
long-term damage even if a satisfactory clinical response to available 
DMARDs has been achieved. Thus, targeting FLS might be necessary in 
a subset of patients to secure permanent or long-term control of disease.
Cadherin-11 is the first validated target for FLS-directed RA therapy 
(13, 37), and anti–cadherin-11 agents have recently progressed to 
clinical trials in RA in combination with TNF inhibitors. However, 
drugging FLS remains in its infancy and, although some DMARDs 
such as JAK inhibitors have been shown to reduce FLS activation 
(12), very few additional FLS-specific candidate targets have been 
identified besides cadherin-11 (4). In addition, most putative FLS 
targets lack the key lines of evidence that are needed to fully validate 
them for anti-FLS/DMARD combination approach in RA. For ex-
ample, it was only recently demonstrated that FLS play a role in CIA 
(10), and no study of an anti-FLS agent has been reported in CIA or 
other adaptive immunity–driven RA models. Also, the ideal anti- 
FLS agent would lack any direct immunomodulation activity, however 
for none of the currently known FLS targets has a mechanism of 
action involving innate or adaptive immune cells been rigorously 
excluded. Perhaps more unexpectedly, no studies of FLS-targeted 
agents in combination with immunosuppressive DMARDs in models 
of RA have been reported. Because many critical proteins involved 
in FLS pathophysiology—including cadherin-11 (37)—are induced 
by arthritogenic cytokines, a preliminary assessment of pharmaco-
logical synergies of any new potential FLS target with immunosuppres-
sive DMARDs would be desirable. However, it is currently unknown 
whether DMARDs influence the expression of cadherin-11 or other 
therapeutic targets in RA FLS.
Here, by focusing on PTPRS as a candidate target for FLS-directed 
RA therapy, we provide multiple levels of proof-of-principle evidence 
that targeting FLS with an anti-PTPRS agent is a viable strategy for 
RA. First, we show that Ig1&2 potently prevents cartilage and bone 
damage and reverses inflammation in multiple mouse models of innate 
and adaptive immunity–driven arthritis. The marked protection from 
cartilage and bone damage achieved via Ig1&2 monotherapy, coupled 
with the enrichment of PTPRS in synovial lining FLS, supports the 
results of a recent report proposing that synovial lining FLS are the 
main and direct mediators of cartilage damage in RA (10) and 
strongly promote bone erosion via secretion of osteoclast-promoting 
factors [i.e, RANKL (receptor activator of nuclear factor kappa-B li-
gand)] and perhaps additional mechanisms (7, 10).
Our bone marrow chimera experiments clearly point to radio-
resistant cells as the key mediators of Ig1&2 efficacy in arthritis. Low 
Fig. 6. TNF regulates PTPRS expression in RA FLS through the PI3K/GSK3/USF2 pathway. (A and B) Expression of PTPRS in RA FLS (n = 5) stimulated with TNF 
(5 ng/ml) for 12 hours in the presence of NFB or PI3K inhibitors (A) or after inhibition of GSK3 (B) in serum starved RA FLS (n = 5) using two different GSK3 inhibitors. 
(C) Epigenomic landscape of the PTPRS locus in one representative RA FLS line. Yellow box indicates PTPRS promoter region with highlight of DNase and transcription 
factor cluster around exon 1 obtained from the UCSC Genome Browser. (D) Expression of PTPRS in RA FLS (n = 4) cultured in normal growth media after transfection with 
either scrambled (siCtrl) or USF2-targeting (siUSF2) siRNA. (E) ChIP assay of USF2 binding to the promoter region of PTPRS. Representative of three independent experi-
ments (n = 3) performed in technical triplicates. (F) Luciferase reporter assay of the promoter region of PTPRS in HEK293T cells after transfection with empty or USF2 ex-
pressing vector. Right panel shows expression of USF2 in transfected HEK293T cells. Representative of two independent experiments (n = 2). Graphs represent 
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PTPRS expression levels were detected on joint MHCII−CD64+ tissue- 
resident macrophages, which are considered radioresistant. However, 
because MHCII−CD64+ tissue-resident macrophages play an arthritis- 
protective role (28), it is unlikely that they contribute to the therapeutic 
effect of Ig1&2. Consistent with the previously proposed concept 
that PTPRS has a very limited and cell-restricted expression in im-
mune cells, we find that PTPRS is not expressed on the vast majority 
of immune cells, including neutrophils, in arthritic mice. Our in vitro 
and in vivo assays also did not reveal any significant suppression of 
T cell, B cell, and/or macrophage function, although additional studies 
are warranted to rigorously rule out any potential effects on T cell 
differentiation during early arthritis development. We did confirm 
that PTPRS is highly expressed in pDCs where it reportedly serves 
as a critical inhibitor of type 1 interferon (IFN) production (19). 
Type I IFN reportedly plays a protective role in the K/BxN model of 
arthritis (38). However, pDC depletion did not alter the efficacy of 
Ig1&2 in this model. Further studies are warranted to assess the effect 
of Ig1&2 on pDCs and on the susceptibility and course of infections 
in vivo. However, we believe that it is unlikely that Ig1&2 markedly 
affects type I IFN responses and/or overall causes significant immuno-
suppression in vivo.
While the high expression of PTPRS on lining FLS likely underlies 
the effectiveness of Ig1&2 at protecting arthritic mice from cartilage 
and bone damage, the notable anti-inflammatory effect of Ig1&2 is 
harder to reconcile with known functions of PTPRS and RA FLS 
subset features. PTPRS shows low expression in sublining FLS, which 
are key promoters of immune cell recruitment to inflamed joints 
(10). In addition, Ig1&2 does not influence Toll-like receptor 4 (TLR4)–, 
IL-1–, and TNF-induced transcriptional responses in RA FLS (15). 
Thus, our data suggest that FLS invasiveness per se triggers additional 
yet unknown mechanisms that amplify inflammation in autoimmune 
arthritis. For example, FLS migration might induce release of pro- 
inflammatory/chemotactic matrix components. This hypothesis war-
rants further experimental assessment using Ig1&2; however, rigorous 
testing via genetic manipulation of mice will require the development 
of approaches—not yet available—to selectively delete lining versus 
sublining FLS and/or selective genes in FLS.
Although a confirmation of the relationship between PTPRS and 
TNF expression in additional RA biopsy cohorts is warranted, multi-
ple complementary lines of evidence our study suggest that expression 
of PTPRS in FLS is regulated by TNF via a novel GSK3-dependent 
pathway and induced by TNF inhibition in vivo. We believe that this 
phenomenon underlies the positive synergy shown when treating 
arthritic mice with a combination of Fc-mTNFR and Ig1&2 doses 
that are ineffective alone to reverse arthritis. Thus, we provide here 
proof-of-principle experimental evidence that treatment of mice 
Fig. 7. Therapeutic synergy between Fc-Ig1&2 and Fc-mTNFR in CIA. (A) CIA was induced in male DBA/1J mice. Once arthritis was established, mice were treated 
intraperitoneally with either 0.1 mg of Fc-Ig1&2, Fc-mTNFR (2 mg/kg), combination of 0.1 mg of Fc-Ig1&2 and Fc-mTNFR (2 mg/kg), or vehicle control (n = 8 for each treatment 
group). Arthritis was evaluated by clinical scoring. (B and C) Representative images of H&E and Toluidine blue (TB) staining (B) used for histopathological evaluation of 
synovial inflammation, bone erosion, and cartilage depletion (C) in one hind paw and one front paw isolated from mice in (A). Scale bars, 500 m. (D) Serum level of anti- 
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with a combination of an immunosuppressive DMARD and a non-
immunosuppressive anti-FLS agent enhances control of disease 
activity. In addition, we suggest that assessment of synergy between 
DMARDs and FLS-targeted agents is an important step not only to 
prioritize combinations with positive synergies but also to rule out 
negative synergies for agents targeting the potential FLS targets that 
are induced by inflammatory cytokines.
In conclusion, our study provides the first evidence that a non-
immunomodulating anti-FLS approach works well in multiple models 
of RA and synergizes with TNF blockade in experimental arthritis. 
A limitation of our study is inherent to the exclusive use of mouse 
models of RA, which are known to be unable to recapitulate the full 
pathogenesis of human RA (39). Furthermore, the potential vari-
ability of PTPRS expression in different patient subsets (e.g., naïve 
versus treated and DMARD-sensitive versus DMARD-resistant) re-
mains to be established. Nevertheless, we provide for PTPRS a level 
of validation never achieved so far for a potential target of FLS-directed 
RA therapy, and we hope that our data will pave the way to further 
translation of anti-FLS and anti-PTPRS approaches to the clinic.
The notable clinical effectiveness of Ig1&2 when administered 
alone in CIA suggests that anti-PTPRS agents might be effective as 
a monotherapy. Although no clinically evident safety signal emerged 
from our in vivo studies thus far, any potential translation of anti- 
PTPRS agents will require a thorough assessment of their safety 
profile. Because even subtherapeutic doses of Ig1&2 could be useful 
in combination with TNF inhibitors, we believe that development 
of anti-PTPRS agents as synergistic combinations with TNF blockers 
would maximize their efficacy/side effects ratio and enhance chances 
of successful commercialization.
MATERIALS AND METHODS
Preparation of human synovial fluids, FLS lines, 
and synovial tissues
Synovial fluids were collected before a research synovial biopsy proce-
dure [University of California, San Diego Institutional Review Board 
(UCSD IRB) protocol no. 160920] by needle aspiration from the knees 
of three individual patients with RA (RA1, RA2, and RA3; two 
females and one male), all with anti-CCP-positive RA meeting 
(American College of Rheumatology/European League against 
Rheumatism) ACR/EULAR criteria and high-grade synovitis with 
palpable joint effusions (UCSD IRB protocol no. 140175). The 
fluids were aliquoted, snap- frozen neat immediately after collection, 
and used after deidentification.
FLS were obtained from the UCSD Clinical and Translational 
Research Institute Biorepository and from the Showa University 
Division of Rheumatology. Each line was previously obtained from 
discarded synovial tissue from different patients with RA undergoing 
synovectomy, as described in (40). The diagnosis of RA conformed 
to the ACR 1987 revised criteria (41), and the diagnosis of OA con-
formed to the ACR 1986 or 1991 criteria (42, 43). FLS were collected 
and used for experiments as approved by the UCSD IRB under pro-
tocol no. 140175 and the Showa University School of Medicine IRB 
under protocol no. 1430 or used for experiments as approved by 
the La Jolla Institute for Immunology IRB under protocol no. 
CB-120-0614.
Synovial complementary DNA (cDNA) and synovial tissue speci-
mens from patients with RA were obtained by the William Harvey 
Research Institute under approved IRB protocol nos. 05/Q0703/198 
and 10/H0801/47 (clinical characteristics are reported in fig. S8F). 
Human synovial tissue specimens used for IF were obtained from 
patients with RA or OA during joint replacement surgery at the 
Sahlgrenska University Hospital. The procedures were approved by 
the Ethics Committee of Gothenburg under protocol no. 573-07. All 
patients signed consent forms approved by the local IRBs.
FLS were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Corning) with 10% fetal bovine serum (FBS; Omega Scientific), 2 mM 
l-glutamine, gentamicin (50 g/ml), penicillin (100 U/ml), and strep-
tomycin (100 g/ml) (Life Technologies) at 37°C in a humidified 
atmosphere containing 5% CO2. For all experiments, FLS were used 
between passages 4 and 10, and the cells were synchronized in 0.1% FBS 
(serum starvation medium) for 24 to 48 hours before experiments 
unless otherwise noted.
Human dermal fibroblasts
Dermal fibroblast lines from healthy human donors (NHDF) were 
isolated from skin specimens obtained from the National Disease 
Research Interchange (NDRI) as described (44). NHDF was cultured 
in the same complete DMEM and conditions as FLS. For all experi-
ments, NHDF was used between passages 3 and 8, and cells were 
synchronized in serum starved media with 0.1% FBS for 24 hours 
before analysis or functional assays.
Preparation of mouse FLS lines
Elbow, knee, and ankle joints from 8-week-old BALB/c mice were 
isolated. Minced tissues were digested in collagenase IV (0.5 mg/ml) 
in RPMI 1640 for 2 hours at 37°C with gentle agitation and cultured 
in the same complete DMEM and conditions as human FLS. Murine 
FLS were used between passages 4 and 10 and synchronized over-
night in 0.1% FBS (serum starvation media) before experiments un-
less otherwise noted.
Synovial fluid stimulations
Confluent human RA FLS were serum starved in DMEM containing 
0.1% FBS. FLS were then stimulated with synovial fluids (diluted 
1:10 in the media). Cells were harvested for RNA extraction after 
12 hours of stimulation. Expression of PTPRS and IL6 was analyzed 
by qPCR and normalized toward the expression of GAPDH.
Assays with signaling inhibitors
RA FLS were serum starved in DMEM containing 0.1% FBS. FLS 
were then were preincubated with either 0.5 M NFB inhibitor 
Bay 11-7085 (Sigma-Aldrich) or 1 M PI3K inhibitor LY294002 
(Cell Signaling Technology) for 1 hour before stimulation with TNF 
(5 ng/ml) for 12 hours. For inhibition of GSK3, serum starved RA 
FLS were treated with either 20 M GSK3 inhibitor SB 415286 
(iGSK3_1; Sigma-Aldrich) or 20 nM GSK3 inhibitor A1070722 
(iGSK3_2; Tocris Bioscience) for 12 hours.
FLS migration assay
Confluent FLS were serum starved for 24 hours in DMEM contain-
ing 0.1% FBS, harvested by trypsin digestion, and seeded at 5 × 104 
cells in 100 l of serum-free DMEM containing 0.5% bovine serum 
albumin (BSA) in the upper chamber of a 6.5-mm-diameter Tran-
swell polycarbonate culture insert with a pore size of 8 m (Costar). 
Inserts were placed in 24-well plates with 600 l of DMEM contain-
ing 10% FBS. The assay plates were incubated in presence/absence 
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inserts were removed, and the upper chamber was gently wiped with 
a cotton swab to remove nonmigrating cells. Transwell membranes 
were fixed for 5 min in methanol and stained for 30 min in 0.2% crys-
tal violet in 2% ethanol. Cells were visualized using a Motic AE2000 
microscope at 10×. Cells were quantified by counting four nonover-
lapping fields using ImageJ software [National Institutes of Health 
(NIH), version 1.8.0_201]. For migration in the presence of TNF, 
RA FLS were serum starved for 24 hours and then pretreated with 
TNF (50 ng/ml) for an additional 24 hours after which cells were 
seeded as for the migration assay. TNF (50 ng/ml) was also added in 
combination with Fc-Ig1&2 during the migration assay.
FLS invasion assay
For invasion assays, cells were seeded as for migration assay, except 
that Corning BioCoat Matrigel Invasion Transwell chambers were 
used. The assay plates were incubated for 48 hours before staining 
and imaging as described for migration assay.
For invasion through type I collagen, 8-m transwells were coated 
with rat tail type I collagen coating solution (Cell Application Inc., 
cat. no. 122-20). The solution was diluted in phosphate-buffered 
saline (PBS) to obtain a final concentration of 30% type I collagen. 
Inserts were coated with 15 l (thin gel, 50 l/cm2 for a total area of 
0.33 cm2) of a 30% type I collagen solution (0.015 g/l), and the 
matrix was left to polymerize at 37°C for 90 min. Then, 5 × 104 cells 
were seeded as described for the invasion assay. The assay plates were 
incubated in the presence/absence of 20 nM Fc-Ig1&2 for 48 hours 
before staining and imaging as described for the migration assay.
Scratch wound migration assay
RA FLS were grown to confluence in six-well plates and serum 
starved for 24 hours in DMEM with 0.1% FBS. Cells were scratched 
with a 1-ml pipette tip and incubated in DMEM containing 1% FBS 
in the presence of 20 or 40 nM Fc-Ig1&2 or vehicle control. Four 
images of the wound were captured right after wounding (0 hour) 
and after 24 hours using a Motic AE2000 microscope at 4× with the 
software ToupView 3.7. Wound area was calculated using the 
ImageJ (NIH, version 1.8.0_201) software, and the wound area after 
24 hours was normalized to the area at 0 hour.
Proliferation assay
Human RA FLS were harvested and seeded at 7.5 × 103 cells per well 
in a 96-well plate and serum starved for 24 hours in DMEM con-
taining 0.1% FBS. Then, FLS were allowed to proliferate for 24 hours 
in response to 10% FBS in DMEM. The CyQUANT NF Cell Prolif-
eration Assay Kit (Invitrogen, cat. no. C35007) was used to measure 
cellular DNA via fluorescent dye binding according to the manufac-
turer’s instructions. In brief, cells were washed with PBS and then 
incubated with 100 l of DNA dye binding solution for 45 min at 
37°C. The extent of proliferation was determined by comparing cell 
counts for samples treated with either 20 nM Fc-Ig1&2 or vehicle. 
The fluorescence intensity of each sample was measured using a mi-
croplate reader with detection at 530 nm.
IF staining of synovial tissue
Paraformaldehyde-fixed paraffin-embedded synovial tissues from 
RA (n = 5) and OA (n = 4) (obtained from orthopedic joint replace-
ment surgery) were deparaffinated in xylene rehydrated and sub-
jected to antigen retrieval using citrate buffer in a pressure chamber 
(2100 Retriever, Aptum Biologics Ltd., Southampton, UK). Non-
specific binding was blocked using serum-free protein block (DAKO). 
Slides were incubated with mouse monoclonal anti-human PTPRS 
(1H6, Abnova) and rat anti-human podoplanin (NZ-1, Thermo 
Fisher Scientific) for 60 min at room temperature, followed by highly 
cross-absorbed secondary goat anti-mouse/rat Alexa Flour–conjugated 
antibodies (488/555, respectively). Hoechst was used for nuclear 
stain. Threshold for positive signal was set by staining with negative 
control mouse IgG (DAKO). Images were collected on a Zeiss LSM 
700 confocal microscope and analyzed with Zen software. Serial tissue 
sections were subjected to hematoxylin and eosin (H&E) staining 
for histologic evaluation.
IHC of synovial tissue
Mouse monoclonal anti-human PTPRS antibody was obtained from 
Abnova, and control IgG antibody (unconjugated goat anti-mouse 
IgG) was purchased from Vector Laboratories (AI-1000). Paraffin- 
embedded slides of human RA synovial tissue were deparaffinated 
in xylene, rehydrated, and pretreated for 10 min with boiling citrate 
antigen retrieval buffer [1.9 mM citric acid and 10 mM tris-sodium 
citrate (pH 6.0)] and then treated with 3% H2O2 for 10 min to 
quench endogenous peroxidases. Slides were blocked with 5% goat 
serum for 1 hour at room temperature and then incubated with anti- 
PTPRS antibody or control rabbit IgG (1:200 in 5% BSA) overnight 
at 4°C. Slides were washed and incubated with SignalStain Boost IHC 
(immunohistochemistry) Detection reagent (Cell Signaling Technology) 
for 30 min, incubated for 2 min with 3,3′-diaminobenzidine substrate, 
and counterstained with hematoxylin. Slide images were obtained 
using an Axio Scan.Z1 slide scanner (Carl Zeiss Microscopy).
Immunoblotting
Cells were lysed in TNE buffer [50 mM tris-HCl (pH 7.5), 150 mM 
NaCl, and 5 mM EDTA (pH 8.0)] containing 1 mM phenylmeth-
anesulfonyl fluoride, 1× protease inhibitor cocktail (Roche), and 
PhosSTOP (Sigma-Aldrich). Protein concentration of cell lysates 
was determined using the Pierce BCA (bicinchoninic acid) Protein 
Assay Kit (Thermo Fisher Scientific). Immunoblotting was performed 
using a goat polyclonal anti-human PTPRS antibody (R&D Systems) 
and a rabbit anti–glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) antibody from Cell Signaling Technology.
Quantitative real-time RT-PCR
RNA was extracted using the RNeasy kit (Qiagen). cDNA was syn-
thesized using the SuperScript III First-Strand Synthesis SuperMix 
for real-time quantitative reverse transcription PCR (qRT-PCR) (Life 
Technologies). qPCR was performed on a Bio-Rad CFX384 Real- 
Time PCR Detection System, with primer assays and SYBR Green qPCR 
Master Mix from SABiosciences/Qiagen. Primer assay efficiencies were 
guaranteed by the manufacturer to be greater than 90%. Each reaction 
was measured using technical triplicates, and data were normalized 
to the expression levels of the housekeeping gene GAPDH. Results 
are presented as fold change compared to either the expression level in 
control samples with the Cq method or as fold change compared to 
the expression of GAPDH.
Mice
All animal experiments were carried out in accordance with the In-
stitutional Animal Care and Use Committee–approved protocol 
(no. AP140-NB4-0610) at the La Jolla Institute for Immunology and 
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generated as previously described in (45). DBA/1J (JAX 000670, 
DBA/1J), BALB/c (JAX 000651, BALB/cJ), and CD45.1 BALB/c 
[JAX 006584, CByJ.SJL(B6)-Ptprca/J] were obtained from the Jackson 
laboratory. BALB/c Rag2-KO mice were obtained from Taconic 
(model 601). KRN mice on the C57BL/6 background were a gift 
from C. Benoist (Harvard University). Nonobese diabetic (NOD) mice 
were obtained from Taconic.
Arthritis models
KRN and NOD mice were crossed to obtain offspring that developed 
arthritis at around 6 to 7 weeks of age (spontaneous K/BxN mice). 
Serum from arthritic K/BxN mice was pooled for use in the K/BxN 
STIA model (27). To elicit STIA, 6- to 8-week-old mice were injected 
intraperitoneally with 100 l of arthritogenic K/BxN serum. Severity 
of arthritis was evaluated by clinical scoring (as described below) 
and measurement of ankles swelling every other day, starting on the 
day of serum injection.
The CIA model was performed as described in (46). Briefly, 8- to 
10-week-old male DBA/1J mice were immunized with 100 g of 
chicken type II collagen (Chondrex) emulsified in Freund’s adjuvant 
containing 50 g of Mycobacterium tuberculosis [H37Ra; American 
Type Culture Collection (ATCC) 25177] [CFA (complete Freund’s ad-
juvant), Sigma-Aldrich]. After 28 days, mice were boosted with 100 g 
of chicken type II collagen emulsified in incomplete Freund’s adju-
vant (Sigma-Aldrich). In all models, arthritis was clinically scored in 
wrists and ankles as previously described (15): 0 = normal; 1 = min-
imal erythema and mild swelling; 2 = moderate erythema and mild 
swelling; 3 = marked erythema and severe swelling, digits not yet in-
volved; and 4 = maximal erythema and swelling, digits involved.
In vivo administration of His-Ig1&2, Fc-Ig1&2,  
and Fc-mTNFR
Preparation of recombinant PTPRS 6xHisIg1&2 (here called His-
Ig1&2) is described in (15). Preparation of human IgG1-Fc–fused 
Ig1&2 (here called Fc-Ig1&2) was contracted to LakePharma (USA). 
Murine TNF-blocking biologic p75TNFR:Fc (Fc-mTNFR) was ob-
tained from Amgen through the Amgen Extramural Research Alliance 
Program. His-Ig1&2 in tris-buffered saline (TBS) or vehicle control 
(TBS), Fc-Ig1&2 in 20 mM tris with 120 mM NaCl or human IgG1-Fc 
control, and Fc-mTNFR was administered according to the schedule 
described in the figure legends.
In vivo pDC depletion
pDCs were depleted in mice by two administrations of 500 g of 
anti–PDCA-1 (InVivoMAb anti-mouse CD317; BioXCell) or IgG 
isotype control (BioXCell) by intraperitoneal or retro-orbital (r.o.) 
injection 2 days apart.
Measurement of serum anti-collagen antibody levels
Anti-collagen antibody levels in sera of mice immunized with col-
lagen were measured by enzyme-linked immunosorbent assay as 
described (46). Briefly, low-binding 96-well multi-well plates (Costar) 
were coated with type II chicken sternal collagen (1 g/ml; Sigma- 
Aldrich). Sera were incubated in serial dilutions, and IgG binding 
to collagen was detected using a biotinylated anti-mouse IgG 
antibody (Jackson ImmunoResearch) as well as anti-mouse IgG1, 
IgG2a, IgG2b, and IgG3 antibodies (SouthernBiotech), followed by 
incubation with extravidin–horseradish peroxidase (Sigma-Aldrich) 
and exposure with 3,3′,5,5′-tetramethylbenzidine (TMB) substrate. 
Plate absorbance was read at 450 nm using a Tecan Infinite M1000 
plate reader.
Histological scoring of mouse arthritic joints
Whole hind paws were fixed in 10% formalin, decalcified, trimmed, 
and embedded. Sections were prepared from tissue blocks and stained 
with H&E, Safranin O, or Toluidine blue by HistoTox Labs. Histo-
pathological scoring was performed as described (15). Briefly, joints 
of arthritic mice were assigned scores of 0 to 4 for inflammation based 
on H&E staining, according to the following criteria: 0 = normal; 
1 = minimal infiltration of inflammatory cells in periarticular area; 
2 = mild infiltration; 3 = moderate infiltration; and 4 = marked in-
filtration. Joints of arthritic mice were given scores of 0 to 4 for bone 
resorption based on H&E staining, according to the following criteria: 
0 = normal; 1 = minimal (small areas of resorption, not readily ap-
parent on low magnification); 2 = mild (more numerous areas of 
resorption, not readily apparent on low magnification, in trabecular 
or cortical bone); 3 = moderate (obvious resorption of trabecular 
and cortical bone, without full thickness defects in the cortex; loss 
of some trabeculae; lesions apparent on low magnification); and 
4 = marked (full-thickness defects in the cortical bone and marked 
trabecular bone loss). Cartilage depletion was identified by dimin-
ished Safranin O or Toluidine blue staining of the matrix and 
was scored on a scale of 0 to 4, where 0 = no cartilage destruction 
(full staining with Safranin O or Toluidine blue), 1 = localized carti-
lage erosions, 2 = more extended cartilage erosions, 3 = severe cartilage 
erosions, and 4 = depletion of entire cartilage. Histologic analyses 
were performed in a blinded manner. Images of whole ankles were 
acquired using a Zeiss Axioscan.Z1 (Zeiss) slide scanner and ana-
lyzed using Zen software (Zeiss).
Micro–computed tomography analysis
Mouse ankles were placed in 10% neutral-buffered formalin. After 
fixation, samples were transferred to 70% ethanol. Before scanning, 
bones were transferred to PBS for 48 hours. Scanning was performed 
on a Skyscan1176 Micro-CT (Bruker) with a voxel size of 9 m, at 
50 kV/200 mA, with a 0.5-mm aluminum filter. Exposure time was 
810 ms. The x-ray projections were obtained at 0.4° intervals with a 
scanning angular rotation of 180° and a combination of four aver-
age frames. The projection images were reconstructed into three- 
dimensional images using NRecon software (Bruker) and DataViewer 
(Bruker). Data were processed using CT-Analyzer software (Bruker), 
and images were generated using CTVOX software (Bruker). Bone 
erosion was quantified as described in (46).
Radiolabeling of Fc-Ig1&2 and Fc-mTNFR
To allow for radiolabeling, the agents were first functionalized with 
DOTA (tetraxetan) to provide chelation sites to attach the radioactive 
atom. To covalently couple Fc-Ig1&2 to DOTA, typically, 0.8 mg of 
protein was immobilized on 0.5 ml of heparin-agarose beads (Sigma- 
Aldrich) in a total of 1.3 ml of tris (pH 7.3) and 150 mM NaCl. 
DOTA– N-hydroxysuccinimide ester (Macrocyclics) was added at a 
concentration of 0.77 mM and incubated at room temperature for 
30 min. After extensive washing in the same buffer, the protein was 
eluted in 750 mM NaCl and 20 mM tris (pH 8.3), further purified by 
size exclusion chromatography (Bio-Rad SEC 650) and concentrated 
to 12 to 15 mg/ml. Fc-mTNFR was modified in a similar way, except 
that no immobilization on solid support was necessary. The reaction was 
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Following this functionalization step, the conjugates were incu-
bated with 111In for 3 hours at 43°C and purified through a P10 sep-
aration column.
Biodistribution studies
STIA was induced in BALB/c mice by an intraperitoneal injection of 
100 l of K/BxN serum, as described under arthritis models. Injection 
of radiolabeled proteins and subsequent imaging began at the peak of 
arthritis, which occurs 8 days after serum injection. All animals were 
anesthetized with isoflurane before injections and imaging. Each 
animal received an intravenous injection of radiolabeled agent, with 
a dose of approximately 170 Ci per animal. Four arthritic mice were 
injected with approximately 170 Ci of 111In-labeled Fc-Ig1&2 and 
compared with five arthritic mice injected with 280 Ci of 111In- 
labeled Fc-mTNFR. Immediately after injection, each animal was 
loosely restrained on the surface of the -Imager planar gamma im-
aging system (Biospace Lab, Nesles la Vallée, France), with continued 
anesthesia. The animals were placed on their backs with paws loose-
ly taped to the top of the imager and the 111In collimator in place. Each 
animal was imaged for 10 min at 1 and 6 hours and 1, 3, and 5 days 
after injection. Each image also included a standard with 5% of the 
injected dose, placed as a point source next to the animal. Following 
the final image, the mice were sacrificed; and samples were collected 
of blood, bladder, liver, kidney, spleen, heart, lung, brain, eye, and 
paws into plastic scintillation vials, weighed; and the activity in each vial 
was measured in a Gamma 9000 gamma counter (Beckman Coulter, 
Brea, CA). Images were analyzed with GammaVision software, cal-
culations were performed in Excel, and graphs were constructed in 
SigmaPlot. Regions of interest (ROIs) were drawn around the hind 
paws and the standard at each time point. Total counts and ROI 
area were recorded for each ROI and exported into Excel. There, all 
the counts were corrected for decay, and the total counts for each 
ROI were divided by the ROI area to provide a value of signal/area 
for each paw and the standard. All the values for the standards were 
normalized to 5%. This produced a correction factor that allowed 
all paw values to be converted from raw counts into percent of in-
jected dose. The percent of injected dose of both hind paws at each 
time point was averaged together, and the resulting values were 
then averaged across all mice at each time point and plotted. Gamma 
counter values for each organ were used to calculate the percent of 
injected dose per organ uptake at day 5. A value of 72 ml/kg of blood 
was used to calculate the total volume and thus total signal for blood 
in each animal, from a smaller quantity collected at sacrifice. These 
percent of the injected dose per organ values were also compared and 
plotted across each mouse group.
Flow cytometry
Single-cell suspensions were prepared from lymph nodes and spleen. 
For isolation of cells from mouse blood, blood was collected into 2 mM 
EDTA in PBS via r.o. bleed (from live animals) or cardiac puncture 
(from euthanized animals). Erythrocytes were lysed from spleen and 
mouse blood using eBiosience red blood cell lysis buffer (Thermo 
Fisher Scientific). For isolation of synovial cells, ankle joints were 
collected, and the tibia and digits disarticulated by pulling with blunt 
forceps and bone marrow flushed out to avoid bone marrow con-
tamination. Joints were rinsed with PBS and dissociated with Liberase 
(Roche) and deoxyribonuclease I (DNase I) at 37°C for 60 min. 
Cells were preincubated with Fc block (BD Pharmingen) before anti-
body staining. For surface staining, fluorochrome-conjugated anti-
bodies specific for CD3 (17A2), CD19 (6D5), NK1.1 (PK136), CD11b 
(M1/70), CD44 (IM7), Ly6G (1A8), Ly6C (HK1.4), CD45.1 (A20), 
MHCII (M5/114.15.2), CD64 (X54-5/7.1), and CD115 (AFS98) were 
obtained from BioLegend. CD43 (R2/60), PD1 (RMP1-30), GL7 (GL-7), 
CD25 (PC61.5), B220 (RA3-6B2), CD317/BST2 (eBio927), CD62L 
(MEL-14), CD45.2 (104), TCR- (T cell receptor–) (H57-597), CD8 
(53-6.7), and CD4 (RM4-5) were obtained from eBioscience/Thermo 
Fisher Scientific. For intracellular cytokine staining, cells were incubated 
with phorbol 12-myristate 13-acetate (PMA; 20 ng/ml; Sigma-Aldrich) 
and 1 m ionomycin (Sigma-Aldrich) in the presence of brefeldin A 
(3 g/ml; eBioscience/Thermo Fisher Scientific) for 5 hours at 37°C. 
Intracellular staining was performed with the intracellular fixation 
buffer (eBioscience/Thermo Fisher Scientific) and permeabilization 
buffer (eBioscience/Thermo Fisher Scientific). For intracellular stain-
ing of transcription factors, the FoxP3/Transcription Factor Staining 
Buffer Set was used (eBioscience/Thermo Fisher Scientific). Anti-
bodies recognizing FoxP3 (FJK-16s), IL-17A (eBio17B7), and IFN 
(XMG1.2) were obtained from eBioscience/Thermo Fisher Scientific, 
and BCL6 was obtained from BD Biosciences. Dead cells were ex-
cluded from analysis by staining with Fixable Viability dye from 
eBioscience/Thermo Fisher Scientific.
Data were acquired on a ZE5 flow cytometer (Bio-Rad) equipped 
with Everest Software. Analysis was performed using FlowJo soft-
ware (TreeStar). Cell sorting was performed on a FACSAria III in-
strument (BD Biosciences). For flow analysis, anti-mouse PTPRS 
(MédiMabs) was labeled with Alexa Fluor 647 using Mix-n-Stain 
antibody labeling kit (Sigma-Aldrich).
Bone marrow reconstitution
To generate bone marrow chimeras, male BALB/cByJ (CD45.1 con-
genic) mice were lethally irradiated with two doses of 5.5 Gy using 
an RS 2000 Biological irradiator and subsequently administered 
bone marrow from male PTPRS WT or KO congenic CD45.2 donor 
mice. KBxN serum was administered to induce arthritis 8 weeks 
after irradiation. After 7 weeks, chimerism was verified by flow cyto-
metry by staining for the appropriate CD45 allele (anti-CD45.1 and 
anti-CD45.2; eBioscience). The percentage of engraftment in recipient 
mice was greater than 95%.
M1 and M2 polarization of BMDMs
Bone marrow cells were isolated from 8- to 12-week-old BALB/c 
mice. Total bone marrow cells were plated in six-well culture plates 
(2 × 106 cells per well) in complete IMDM (Iscove’s Modified Dulbecco’s 
Medium) media containing 10% FBS, 25 mM Hepes, 2 mM l-glutamine, 
penicillin (100 U/ml), streptomycin (100 g/ml), and macrophage 
colony-stimulating factor (M-CSF; 20 ng/ml) (BioLegend). Non-
adherent cells were removed after 24 hours by washing with PBS 
and replacing with new complete IMDM media containing M-CSF 
(20 ng/ml). Media was replaced every 3 days, and cells were cultured 
for a total of 7 days. After 7 days, BMDMs were left unstimulated 
(M0) or stimulated with either lipopolysaccharide (100 ng/ml; Sigma- 
Aldrich) and IFN (50 ng/ml; BioLegend) for M1 polarization or 
IL-4 (10 ng/ml; BioLegend) and IL-13 (10 ng/ml; BioLegend) for M2 
polarization. Fc-Ig1&2 (20, 40, and 80 nM) was added to the cells 
during polarization. Cells were collected after 24 hours, and RNA was 
extracted using the RNeasy Micro Kit (Qiagen). Expression of M1- 
related genes Tnf, Il1b, Nos2, and Il12 and M2-related genes Pparg, 
Arg1, Retnla, and Mrc1 were analyzed by qPCR. Expression was nor-
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Phagocytosis assay
Bone marrow cells were isolated from 8- to 12-week-old BALB/c 
mice and cultured in 12-well plates (1 × 106 cells per well) under BMDM 
conditions as described above. After 7 days, BMDMs were either 
left unstimulated (M0 condition) or under M1- or M2-polarizing 
conditions as described above. Fc-Ig1&2 (20, 40, or 80 nM) was 
added during M1 and M2 polarization. After 24 hours, polarizing 
media was replaced with IMDM without FBS, and cells were cultured 
for 1 hour in the presence of either Fc-Ig1&2 (20, 40, or 80 nM) or 
vehicle control for 1 hour. After 1 hour, either pHrodo Red E. coli or 
pHrodo Green S. aureus BioParticles (Invitrogen) were added to the cells 
according to the manufacturer’s protocol. Cells were allowed to 
phagocytose bioparticles for 30 min, after which cells were washed, 
detached from plates using TrypLE Express (Thermo Fisher Sci-
entific), stained with Fixable Viability Dye 780 (Thermo Fisher Sci-
entific), and analyzed by flow cytometry. Cells incubated with 
bioparticles on ice were used as negative control for phagocytosis. The 
pH-sensitive dye pHrodo is nonfluorescent at neutral pH but flu-
oresces brightly upon the acidification that occurs in the phagosome.
CD4 T cell differentiation assays
Naïve CD4 T cells were isolated from pooled spleen and lymph 
nodes of either 8- to 12-week-old BALB/c or DBA/1J mice using the 
EasySep Mouse Naïve CD4+ T cell isolation kit (STEMCELL Tech-
nologies). Isolated naïve CD4 T cells were polarized into either TH1, 
TH17, or iTregs  (induced regulatory T cells) in the presence of Fc-Ig1&2 
(20, 40, or 80 nM) or vehicle control using the below described 
conditions.
For differentiation of TH1 cells, 1 × 105 naïve CD4 T cells were 
cultured on anti-CD3 (145-2C11, BioLegend; 2 g/ml)–coated plates 
in complete RPMI 1640 media [10% FBS, penicillin (100 U/ml), 
streptomycin (100 g/ml), 1× nonessential amino acids, 25 mM Hepes, 
55 M -mercaptoethanol, and 2 mM l-glutamine] containing soluble 
anti- CD28 (37.51, BioLegend; 0.5 g/ml), anti–IL-4 (11B11, BioLegend; 
10 g/ml), recombinant mouse IL-12 (R&D Systems; 25 ng/ml), and 
recombinant mouse IL-2 (R&D Systems; 25 ng/ml). For differenti-
ation of TH17 cells, 1 × 105 naïve CD4 T cells were cultured on anti- 
CD3 (145-2C11; 2 g/ml)–coated plates in complete RPMI 1640 
media containing soluble anti-CD28 (37.51; 1 g/ml), anti-IFN 
(XMG1.2, BioLegend; 10 g/ml), anti–IL-4 (11B11, 10 g/ml), re-
combinant human transforming growth factor–1 (TGF1) (R&D 
Systems; 5 ng/ml), and recombinant mouse IL-6 (BioLegend; 50 ng/ml). 
For iTreg differentiation, 1 × 105 naïve CD4 T cells were cultured 
on anti-CD3 (145-2C11; 2 g/ml)–coated plates in complete RPMI 
1640 media containing soluble anti-CD28 (37.51; 0.5 g/ml) and re-
combinant human TGF1 (R&D Systems; 5 ng/ml). Cells were cul-
tured under TH-polarizing conditions for 5 days. To verify TH1 and 
TH17 differentiation, cells were stimulated with PMA (20 ng/ml) and 
ionomycin (1 M) in the presence of brefeldin A (Thermo Fisher 
Scientific; 3 g/ml) for 4 hours and analyzed by flow cytometry for 
the expression of IFN and IL-17A. To verify iTreg differentiation, 
cells were analyzed by flow cytometry for the expression of FoxP3. 
Cells cultured without polarizing conditions (TH0) were used as con-
trol for polarization.
In a second experiment, we performed polarization of naïve CD4 
T cells in the presence of APCs. Naïve CD4 T cells (1 × 105), isolated 
from BALB/c mice, were cultured with 1 × 105 irradiated BALB/c 
Rag2-KO splenocytes (35 Gy) as APCs and soluble anti-CD3 
(145-2C11, BioLegend; 5 g/ml) under TH1-, TH17-, or iTreg-polarizing 
conditions. The same polarizing conditions as described above were 
used; however, soluble anti-CD28 was removed because of the pres-
ence of irradiated APCs. Differentiation of TH1, TH17, and iTregs was 
verified as described above.
Epigenetic evaluation of the PTPRS and SDC4 loci
Data used for evaluation of the epigenetic and transcriptomic land-
scape in the PTPRS and SDC4 loci in RA (n  =  10 lines) and OA 
(n = 10 lines) FLS were obtained as described previously (23). Data 
are available in the Gene Expression Omnibus with the primary ac-
cession code GSE112658. Images were generated using Integrative 
Genomics Viewer version 2.3.98. USF2-binding sites in the PTPRS 
promoter region were identified using the UCSC Genome Browser 
(GRCh37/hg19) together with the Transcription Factor ChIP se-
quencing clusters from ENCODE (version March 2012) and DNase 
I Hypersensitivity Clusters from ENCODE (V3).
Transfection and dual-luciferase reporter assay
Dual-luciferase assays were performed in human embryonic kidney 
(HEK) 293T cells obtained from the ATCC. Confluent HEK293T 
cells were transfected using polyethylenimine (PEI) in a ratio of 
3 to 1 per g of plasmid in Opti-MEM. Overexpression vector 
for human USF2 or an empty control vector was obtained from 
VectorBuilder Inc. A luciferase promoter region reporter vector 
containing a 120–base pair portion of the PTPRS promoter region 
(UCSC Genome Browser on Human GRCh37/hg19 position: 
chr19:5,340,976-5,341,095) containing binding sites for USF2 was 
obtained from VectorBuilder Inc. Cells were incubated for 24 hours 
after transfection. Luciferase activity was assessed using the Dual- 
Luciferase Reporter Assay System from Promega according to the 
manufacturer’s protocol. Renilla luciferase activity was used to nor-
malize firefly luciferase activity.
Chromatin immunoprecipitation
RA FLS were cultured to confluency, serum starved for 24 hours, 
and stimulated with recombinant human TNF (50 ng/ml) for 6 hours 
or left unstimulated. Then, cells were fixed in 1% formaldehyde for 
15 min at room temperature. After sonication, chromatin was im-
munoprecipitated with the Pierce Magnetic ChIP assay Kit (Thermo 
Fisher Scientific) using a rabbit anti-USF2 antibody (NBP2-56717, 
Novus Biologicals) overnight at 4°C according to the manufacturer’s 
instructions. The eluted DNA was used for PTPRS promoter region 
PCR and qPCR. Ten percent input for each condition was used for 
normalization. Human PTPRS promoter primers, 5′-TCTGC-
CCCGCTTCACATCG-3′ (forward) and 5′-AGCCGCCACCAC-
CACCACCA-3′ (reverse), were purchased from Integrated DNA 
Technologies and used for ChIP qPCR with the PowerUp SYBR 
Green PCR Master Mix (Thermo Fisher Scientific) and PCR using 
the OneTaq Hot Start Quick-Load 2× Master Mix with GC buffer 
(New England Biolabs Inc.).
siRNA-mediated knockdown
RA FLS were grown to confluency (70%) and transfected with 1 g 
of ON-TARGETplus SMARTpool siRNA-targeting human USF2 
(Dharmacon) or 1 g of ON-TARGETplus Nontargeting Pool siRNA 
(Dharmacon) using the Human Dermal Fibroblast Nucleofector 
Kit (Lonza) according to the manufacturer’s protocol. In brief, 5 × 
105 RA FLS were resuspended in 100 l of nucleofector solution 
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Amaxa Nucleofector II. Transfected cells were divided into three 
individual wells in a six-well plate. Cells were harvested for RNA 
extraction after 24 and 48 hours, and expression of USF2 and PTPRS 
was analyzed by qPCR and normalized toward the expression of 
GAPDH as described above. Fold change in expression was calculated 
against the expression in RA FLS treated with control siRNA using 
the CT method.
Statistical analysis
Sample sizes were selected on the basis of our experience with the 
assays being performed to achieve sufficient power to detect biologi-
cally relevant differences in the experiments being conducted. The 
two- or one-way analysis of variance (ANOVA), Spearman correla-
tion, Kruskal-Wallis, paired or unpaired t test, paired ratio t test, and 
Mann-Whitney U test were performed where appropriate as reported 
in the figure legends. Parametric tests were only used on normally 
distributed variables as assessed by the Shapiro-Wilk test. All statis-
tical analyses were performed using GraphPad Prism software. A 
comparison was considered significant if P was less than 0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
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